Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v2.4.0.6
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)
In Thousands, except Share data
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Total
Balances at Mar. 31, 2011 $ 17 $ 128,977 $ (167) $ (119,418) $ 9,409
Balances (in shares) at Mar. 31, 2011 1,688,943        
Common stock repurchases 0 0 0 0 0
Common stock repurchases (in shares) (136)        
Stock compensation expense 0 175 0 0 175
Warrants exchanged for services 0 (100) 0 0 (100)
Net loss 0 0 0 (1,429) (1,429)
Cumulative translation adjustment 0 0 25 0 25
Balances at Mar. 31, 2012 17 129,052 (142) (120,847) 8,080
Balances (in shares) at Mar. 31, 2012 1,688,807       1,688,807
Stock issued for asset acquisition - CollabRx 2 930 0 0 932
Stock issued for asset acquisition - CollabRx (in shares) 236,433        
Stock compensation expense and released restricted stock units 0 695 0 0 695
Stock compensation expense and released restricted stock units (in shares) 27,740        
Warrants exchanged for services 0 (75) 0 0 (75)
Net loss 0 0 0 (3,928) (3,928)
Balances at Mar. 31, 2013 $ 19 $ 130,602 $ (142) $ (124,775) $ 5,704
Balances (in shares) at Mar. 31, 2013 1,952,980       1,952,980